Contact your GP within 2448 hours if headaches progressively worsen despite simple painkillers, persist beyond 48 weeks of stable dosing, or significantly interfere with daily activities
Eli Lilly and Company Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
They mimic the natural hormone GLP-1, which: Stimulates insulin secretion Suppresses glucagon (a hormone that raises blood sugar) Delays gastric emptying (keeping you full longer) Reduces appetite via brain satiety centers This combination of effects leads to significant weight loss, improved blood sugar control, and reduced cardiovascular risks, especially when combined with lifestyle and plant-based care
The risk of pancreatitis can be minimized by addressing and mitigating risk factors from previous episodes, regulating the rate of weight loss by adjusting the GLP-1 receptor agonist dose and the content and frequency of meals, closely monitoring patients during GLP-1 receptor agonist therapy, and implementing appropriate precautionary measures
Essential tracking metrics For each injection: Date, time, dose in mg, syringe units drawn, injection site, concentration of current vial, days since vial reconstitution
Glucagon-like peptide-1 receptor agonists in the treatment of idiopathic inflammatory myopathy: from mechanisms of action to clinical applications
